<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343613</url>
  </required_header>
  <id_info>
    <org_study_id>16786</org_study_id>
    <secondary_id>I9L-MC-JZCA</secondary_id>
    <secondary_id>2017-002693-39</secondary_id>
    <nct_id>NCT03343613</nct_id>
  </id_info>
  <brief_title>A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the study drug LY3381916 administered
      alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody
      (LY3300054).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to strategic business decision by Eli Lilly and Company.
  </why_stopped>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Actual">May 4, 2020</completion_date>
  <primary_completion_date type="Actual">February 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
    <description>Number of participants with DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3381916</measure>
    <time_frame>Predose Lead in Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: Cmax of LY3381916</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Plasma Concentration Curve (AUC) of LY3381916</measure>
    <time_frame>Predose Lead in Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: AUC of LY3381916</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3381916 Administered in Combination with LY3300054</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: Cmax of LY3381916 administered in combination with LY3300054</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of LY3381916 Administered in Combination with LY3300054</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: AUC of LY3381916 administered in combination with LY3300054</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3300054 Administered in Combination with LY3381916</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: Cmax of LY3300054 administered in combination with LY3381916</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Minimum Plasma Concentration (Cmin) of LY3300054 Administered in Combination with LY3381916</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1</time_frame>
    <description>PK: Cmin of LY3300054 administered in combination with LY3381916</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 12 Months)</time_frame>
    <description>ORR: Percentage of participants with a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Baseline to Date of CR or PR (Estimated up to 12 Months)</time_frame>
    <description>TTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 12 Months)</time_frame>
    <description>DCR: Percentage of participants who exhibit SD, CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated Up to 12 Months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LY3381916 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 + LY3300054 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally and LY3300054 administered intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3381916 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 + LY3300054 Expansion B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metastatic triple negative breast cancer (TNBC)
LY3381916 administered orally and LY3300054 administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 + LY3300054 Expansion B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metastatic non-small cell lung cancer (NSCLC)
LY3381916 administered orally and LY3300054 administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3381916 + LY3300054 Expansion B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metastatic clear cell carcinoma renal cell carcinoma (RCC)
LY3381916 administered orally and LY3300054 administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3381916</intervention_name>
    <description>IDO-1 inhibitor administered orally</description>
    <arm_group_label>LY3381916 + LY3300054 Escalation</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion B1</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion B2</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion B3</arm_group_label>
    <arm_group_label>LY3381916 Escalation</arm_group_label>
    <arm_group_label>LY3381916 Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3300054</intervention_name>
    <description>PD-L1 inhibitor administered IV</description>
    <arm_group_label>LY3381916 + LY3300054 Escalation</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion B1</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion B2</arm_group_label>
    <arm_group_label>LY3381916 + LY3300054 Expansion B3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dose escalation phase: Participant must have histological or cytological evidence of a
             diagnosis of cancer that is advanced and/or metastatic.

          -  Dose expansion B1: Metastatic TNBC participants who have not received prior PD-1/L1
             treatment.

          -  Dose expansion B2: Metastatic NSCLC participants who have progressed on prior PD-L1/L1
             treatment.

          -  Dose expansion B3: Metastatic clear cell carcinoma RCC who have progressed on prior
             PD-L1/L1 treatment.

          -  Have adequate organ function.

          -  Have a performance status (PS) of â‰¤1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

          -  Are able and willing to provide required, newly acquired tumor biopsies.

          -  Have discontinued previous treatments for cancer.

          -  Are able to swallow capsules.

        Exclusion Criteria:

          -  Currently enrolled in a clinical study.

          -  Have known symptomatic central nervous system metastases or carcinomatous meningitis.

          -  Have a serious concomitant systemic disorder.

          -  Have a symptomatic human immunodeficiency virus infection or symptomatic
             activated/reactivated hepatitis B or C.

          -  Have a significant cardiac condition.

          -  Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor.

          -  Have an active autoimmune disease or currently require immunosuppression of &gt;10
             milligrams of prednisone or equivalent per day.

          -  Have interstitial lung disease or (noninfectious) pneumonitis, participants with a
             history of (noninfectious) pneumonitis that required steroids to assist with
             management.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IU Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finsen Institute</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Umberto I</name>
      <address>
        <city>Ancona</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/5sqQ8KzLnN79i471hIpC0c?conditionId=LcQNUbMtMWSEYwOSaGUIi</url>
    <description>A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDO-1 Inhibitor</keyword>
  <keyword>IDO1 Inhibitor</keyword>
  <keyword>IDO Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

